sb 203580 has been researched along with zofenoprilate in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (zofenoprilate) | Trials (zofenoprilate) | Recent Studies (post-2010) (zofenoprilate) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 19 | 1 | 4 |
| Protein | Taxonomy | sb 203580 (IC50) | zofenoprilate (IC50) |
|---|---|---|---|
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.008 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciccarelli, C; Desideri, G; Evangelista, S; Ferri, C; Festuccia, C; Grassi, D; Gravina, GL; Lovat, F; Marampon, F; Polidoro, L; Scarsella, L; Zani, BM | 1 |
1 other study(ies) available for sb 203580 and zofenoprilate
| Article | Year |
|---|---|
Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Captopril; Cell Nucleus; Cell Survival; Endothelial Cells; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; MAP Kinase Kinase 6; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyridines; Reactive Oxygen Species; Sirtuin 1; Superoxides | 2013 |